VIT-RACIBORSKA

Regimen

Experimental
Vincristine + irinotecan + temozolomide (VIT)
Control
None (historical)

Population

Relapsed or refractory Ewing sarcoma across pediatric centers in Poland

Key finding

Consistent ~60-70% ORR in relapsed Ewing with outpatient-delivered triplet. One of several VIT cohorts (MSK, CHOP, Warsaw, Virginia) that collectively established VIT without ever running an RCT. rEECur 2024 is now superseding it with high-dose ifosfamide.

Source: PMID 23776128

Timeline

    Guideline citations

    • NCCN BONE (p.32)